- Home
- SPGC vs LIXT Comparison
SPGC vs LIXT Comparison
Compare SPGC & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPGC
- LIXT
- Stock Information
- Founded
- SPGC 2018
- LIXT 2005
- Country
- SPGC United States
- LIXT United States
- Employees
- SPGC N/A
- LIXT N/A
- Industry
- SPGC
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SPGC
- LIXT Health Care
- Exchange
- SPGC Nasdaq
- LIXT Nasdaq
- Market Cap
- SPGC 3.6M
- LIXT 4.2M
- IPO Year
- SPGC 2023
- LIXT N/A
- Fundamental
- Price
- SPGC $1.66
- LIXT $1.62
- Analyst Decision
- SPGC
- LIXT
- Analyst Count
- SPGC 0
- LIXT 0
- Target Price
- SPGC N/A
- LIXT N/A
- AVG Volume (30 Days)
- SPGC 102.7K
- LIXT 1.8M
- Earning Date
- SPGC 11-14-2024
- LIXT 11-12-2024
- Dividend Yield
- SPGC N/A
- LIXT N/A
- EPS Growth
- SPGC N/A
- LIXT N/A
- EPS
- SPGC N/A
- LIXT N/A
- Revenue
- SPGC $2,491,000.00
- LIXT N/A
- Revenue This Year
- SPGC $771.92
- LIXT N/A
- Revenue Next Year
- SPGC $76.31
- LIXT N/A
- P/E Ratio
- SPGC N/A
- LIXT N/A
- Revenue Growth
- SPGC 840.00
- LIXT N/A
- 52 Week Low
- SPGC $1.52
- LIXT $1.31
- 52 Week High
- SPGC $9.17
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- SPGC 34.00
- LIXT 43.04
- Support Level
- SPGC $1.61
- LIXT $1.56
- Resistance Level
- SPGC $2.07
- LIXT $1.87
- Average True Range (ATR)
- SPGC 0.16
- LIXT 0.23
- MACD
- SPGC 0.03
- LIXT -0.03
- Stochastic Oscillator
- SPGC 10.98
- LIXT 8.33
About SPGC Sacks Parente Golf Inc.
Sacks Parente Golf Inc is a technology-forward golf company, with a growing portfolio of golf products, including putting instruments, golf shafts, golf grips, and other golf-related products. It designs, manufactures, and sells technology-forward, golf equipment, which is comprised of putting instruments, golf shafts, golf grips, and related product groups. It designs its golf products to fit golfers of all skill levels, amateur and professional. Its business segments currently include, golf putting instruments, golf shafts, and golf related products.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.